Epizyme Story Overview

EPZM -- USA Stock  

USD 15.85  0.90  6.02%

Macroaxis does not monitor all media channels or aggregates social signals for Epizyme. But even though we do not provide professional-grade financial sentiment analysis on Epizyme, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Epizyme. Additionally see Epizyme Hype Analysis, Epizyme Correlation and Epizyme Performance.
Acquisition by Michael Giordano of 25000 shares of Epizyme subject to Rule 16b-3
Filed transaction by Epizyme Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Epizyme Inc insider trading alert for grant of stock option (right to buy) by Michael Giordano, the corporate stakeholder, on March 12, 2018. This event was filed by Epizyme Inc with SEC on 2018-03-12. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on March 12, 2018 was a factor to the next trading day price appreciation.The overall trading delta against the next closing price was 3.25% . The overall trading delta when the story was published against the current closing price is 14.36% .

Similar stores for Epizyme

few hours ago at www.macroaxis.com 
Exercise or conversion by Andrew Singer of 1682 shares of Epizyme subject to Rule 16b-3
Macroaxis News
Filed transaction by Epizyme Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
few days ago at http://nasdaqplace.com 
Most Active Stocks in Concentration Epizyme, Inc.
nasdaq News
Nasdaq Place Full coverage
over a week ago at http://simplywall.st 
Market Sentiment Around Loss-Making Epizyme Inc
news
Simply Wall StWhy Is Epizyme Up 16.2 percent Since Its Last Earnings Report Zacks.comWere Analysts Bearish Epizyme, Inc. This Week Frisco FastballEpizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data NasdaqFull coverage
Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCObusinessinsider News
Markets InsiderFull coverage
over two weeks ago at http://www.journalfinance.net 
Acquisition by Andrew Allen of 12500 shares of Epizyme subject to Rule 16b-3
news
Filed transaction by Epizyme Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
over three weeks ago at www.macroaxis.com 
Sale by Bay City Capital Llc of 883 shares of Epizyme
Macroaxis News
Filed transaction by Epizyme Inc executive. General open market or private sale of non-derivative or derivative security
over three weeks ago at http://nasdaqtimes.com 
Epizyme, Inc. - Most Active Performers for the Day
nasdaq News
NASDAQ TimesFull coverage
over a month ago at http://thewellesleysnews.com 
Stock-research Ratings Epizyme, Inc. , Monaker Group, Inc.
news
Analyst JournalFull coverage
over a month ago at http://simplywall.st 
Is Epizyme Inc Cheap For A Reason
news
Simply Wall StAnalysts See -0.54 EPS for Epizyme, Inc. as of May, 14 US Index LiveEpizyme Releases Earnings Results, Beats Expectations By 0.05 EPS StockNewsTimesFull coverage
over a month ago at http://friscofastball.com 
-0.54 EPS Expected for Epizyme, Inc.
news
Frisco FastballEpizyme, Inc. Analysts See -0.54 EPS BZ WeeklyFull coverage
over a month ago at http://stockspen.com 
Stocks Volatility Analysis Epizyme Inc
news
Stocks PenFull coverage
over two months ago at http://bangaloreweekly.com 
Epizyme Inc. Upgraded to Buy by Zacks Investment Research
news
BangaloreWeeklyFull coverage

Did you try this?

Run Equity Valuation Now
   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Equity Valuation

Total Asset

Total Asset Comparative Analysis
  Total Asset 
      Epizyme Comparables 
Epizyme is currently under evaluation in total asset category among related companies. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Peers

Epizyme Related Equities
VBIV  6.82 %   
0%
100.0%
NK  4.50 %   
0%
66.0%
VCEL  3.38 %   
0%
49.0%
VBLT  1.89 %   
0%
27.0%
DMPI  0.93 %   
0%
13.0%
DRNA  0.86 %   
0%
12.0%
DOVA  0.13 %   
0%
1.0%
DRRX  4.09 %   
59.0%
0%
DNLI  5.39 %   
79.0%
0%
Additionally see Epizyme Hype Analysis, Epizyme Correlation and Epizyme Performance. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.